• Contact Us
  • News
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Partner With Us
    • Corporate Responsibility
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA™ (glycopyrronium) cloth
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Investors & Media
    • Investor Overview
    • Stock Information
    • News Releases
    • Media Resources
    • Events & Presentations
    • Corporate Governance
    • Financial Filings
    • Investor FAQs
    • Information Request
MENU MENU
mobile logo mobile
close-btn
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Partner With Us
    • Corporate Responsibility
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA™ (glycopyrronium) cloth
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Investors & Media
    • Investor Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price
      • Investment Calculator
      • Analyst Coverage
    • News Releases
    • Media Resources
    • Events & Presentations
    • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Committee Composition
      • Documents & Charters
    • Financial Filings
      • SEC Filings
    • Investor FAQs
    • Information Request
  • Contact Us
  • News
FOLLOW US
borderborder

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A Phase IIa, multicenter, randomized, vehicle-controlled study.

  • Investors Overview
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • News Releases
  • Media Resources
  • Events & Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • Documents & Charters
  • Financial Filings
    • SEC Filings
    • Annual Reports
  • Investor FAQs

Company

  • About Us
  • Leadership
  • Board of Directors
  • Partner With Us
  • Corporate Responsibility
  • Contact Us

Our Focus

  • Overview
  • Hyperhidrosis
  • Atopic Dermatitis
  • Helpful Resources
  • Grants & Sponsorships

OUR MEDICINES

  • QBREXZA™ (glycopyrronium) cloth

R&D

  • Pipeline
  • Lebrikizumab
  • Clinical Trials
  • Early Research Program
  • Medical Information

CAREERS

  • Culture & Values
  • Job Openings

INVESTORS & MEDIA

  • Investor Overview
  • Stock Information
  • News Releases
  • Media Resources
  • Events & Presentations
  • Corporate Governance
  • Financial Filings
  • Investor FAQs
  • Information Request
FOLLOW US
borderborder
  • © 2019 Dermira, Inc.
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
  • Corporate Compliance
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • News
FOLLOW US
borderborder

© 2019 Dermira, Inc.

  • © 2019 Dermira, Inc.
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
PM-US-QBR-0129 9/2018

You Are Now Leaving Dermira.com

RETURN
CONTINUE
PM-US-QBR-0129 9/2018